Tricida, Inc.
7000 Shoreline Court, Suite 201
South San Francisco
California
94080
United States
78 articles with Tricida, Inc.
-
Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical Development
8/1/2018
Dr. Parsell will lead Tricida’s clinical development of TRC101
-
Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
7/2/2018
Tricida, Inc. (NASDAQ: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with...
-
It’s been a pretty good year for biotech initial public offerings (IPOs), with two Bay Area biotechs marking numbers eight and nine for the area.
-
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
-
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
6/5/2018
Tricida, Inc., a late-stage pharmaceutical company, announced results from its pivotal Phase 3 double-blind, randomized, placebo-controlled, multi-center Phase 3 clinical trial, TRCA-301, in 217 chronic kidney disease (CKD) patients with metabolic acidosis.
-
Tricida Announces Kathryn Falberg Joins Board of Directors
6/4/2018
Ms. Falberg is a seasoned pharmaceutical industry executive with extensive leadership and finance expertise.
-
Tricida Announces $100 Million Venture Debt Financing From Hercules Capital
3/2/2018
Tricida, Inc. announced today that it has entered into a $100 million venture debt facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets.
-
Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President
1/8/2018
Dr. van Beek will lead Tricida’s commercial planning and operations functions.
-
Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101.
-
Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase I/II Study Results in Patients With Metabolic Acidosis Associated with Chronic Kidney Disease
11/2/2017
Tricida today announced that David A. Bushinsky, M.D., will deliver a podium presentation at the ASN Annual Kidney Week meeting, taking place November 1-5, 2017 in New Orleans, on the results of Tricida’s successful Phase 1/2 study of TRC101.
-
Tricida Initiates Phase III Study Of TRC101 For The Treatment Of Metabolic Acidosis Associated With Chronic Kidney Disease
9/28/2017
-
Tricida Announces Hiring Of Geoffrey Parker As Chief Financial Officer And Senior Vice President
4/11/2017
-
Tricida Announces Hiring Of Wilhelm Stahl As Chief Technology Officer And Senior Vice President
2/15/2017
-
Tricida Announces Positive Topline Phase I/II Clinical Trial Results For TRC101 In 135 Subjects With Chronic Kidney Disease And Metabolic Acidosis
1/9/2017
-
Bay Area Startup Tricida Nabs $55 Million Series C
7/25/2016
-
Tricida Announces FDA Acceptance Of Investigational New Drug Application For Lead Candidate TRC101 And Hiring Of Claire Lockey As Chief Development Officer And Edward J. Hejlek As General Counsel
1/13/2016
-
Bay Area's Tricida Scores $30 Million
3/4/2015
-
Tricida Announces In-House Discovered Clinical Candidate In Cardiorenal Disease
9/4/2014